These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16670073)

  • 21. Diffuse large B-cell lymphoma.
    Ng AK
    Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma.
    Lee TK; Man K; Poon RT; Lo CM; Ng IO; Fan ST
    Oncol Rep; 2004 Jul; 12(1):25-31. PubMed ID: 15201954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
    Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
    Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
    Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
    Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.
    Rigacci L; Puccini B; Iovino L; Martelli M; Finolezzi E; DI Lollo S; Doria M; Bosi A
    J Chemother; 2011 Aug; 23(4):227-31. PubMed ID: 21803701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
    Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM; Jürgensen GW; Johnsen HE
    Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy.
    Pasanen AK; Haapasaari KM; Peltonen J; Soini Y; Jantunen E; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2013 Jul; 91(1):29-36. PubMed ID: 23560495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM; Wang L; Shen Y; Xia ZG; Chen Y; Chen QS; Chen Y; Zeng XY; You JH; Qian Y; Shen ZX
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
    Mounier N; Briere J; Gisselbrecht C; Reyes F; Gaulard P; Coiffier B;
    Haematologica; 2006 May; 91(5):715-6. PubMed ID: 16670080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of conservative treatment of gastric lymphosarcoma].
    Zvonkov EE; Kremenetskaia AM; Kravchenko SK; Makhinia VA; Kaplanskaia IB; Obukhova TN; Samoĭlova RS; Shevelev AA; Magomedova AU; Bariakh EA; Krasil'nikova BB; Gubkin AV; Iliushkina EA; Mar'in DS; Morozova AK; Kulikov SM; Gemdzhian EG; Vorob'ev AI
    Ter Arkh; 2008; 80(7):18-26. PubMed ID: 18763589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
    Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
    Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
    Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
    Laurent C; Do C; Gascoyne RD; Lamant L; Ysebaert L; Laurent G; Delsol G; Brousset P
    J Clin Oncol; 2009 Sep; 27(25):4211-6. PubMed ID: 19636007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse prognosis of bulky disease in good-risk DLBCL.
    Ribera JM
    Lancet Oncol; 2008 May; 9(5):406-7. PubMed ID: 18452849
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
    García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C
    Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.